Peptides such as oral BPC-157, oral larazotide , oral KPV, and injectable thymosin beta-4 (T4) are well tolerated and can be seamlessly integrated into existing protocols, even for the most sensitive patients
Although MPTP/MPP + is primarily known for its direct toxicity to dopaminergic neurons, recent studies increasingly use murine BV-2 microglial cells to investigate the MPP + effect on microglial activation and neuroinflammation [41,42,43]
There is currently no standardized dosing protocol supported by high-quality human clinical research
Microarray studies have identified changes in the expression of genes involved in cell cycle regulation, apoptosis, and stress response following Epithalon treatment
However, that protection is less secure globally, where patents in some regions, including China and Canada, are due to expire as early as 2026